Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine
베링거표 LAMA+LABA COPD 복합제 국내 상륙 임박
Population-based study of LAMA monotherapy effectiveness compared with LABA/ LAMA as initial treatment for COPD in primary care | npj Primary Care Respiratory Medicine
CAPTAIN: Effects of baseline SABA use on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA | GSK
Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study | GSK
BPCO, cambia l'approccio. Due broncodilatatori la nuova terapia standard - La Gazzetta del Mezzogiorno
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
Toby Capstick on X: "#Trelegy Ellipta: The second ICS/LAMA/LABA inhaler in the UK, licensed for #COPD. https://t.co/NSYtv7bTYS (An alternative ICS/LABA /LAMA inhaler is available: #Trimbow MDI) https://t.co/vQBgh9lvM2" / X
Il ruolo dei LABA/LAMA nel setting del MMG
Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study | Archivos de Bronconeumología
GSKpro GR | Προϊοντική ενημέρωση για Επαγγελματίες Υγείας
LAMA/LABA, '계열 이팩트' 인정 시기상조 < 제약·바이오 < 산업 < 기사본문 - 팜뉴스
BPCO, rimborsabile la triplice terapia fluticasone furoato/umeclidinio/vilanterolo
Per la terapia della BPCO vale la regola del “tre in uno” | GSK in Italia
Forest plots of LAMA/LABA versus TIO at 24 weeks. AE adverse event, CFB... | Download Scientific Diagram
LAMA/LABA therapy reduced risk for COPD exacerbation, pneumonia hospitalization
Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine
LABA/LAMA fixed dose combinations | Download Table
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD | Pulmonary Therapy
Presentazione di PowerPoint
Characteristics and treatment pathways of patients with COPD receiving a long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) in the UK | GSK
Comparison of various drugs in development of combination therapy with... | Download Table
ANORO ELLIPTA Mechanism of Action (MOA)
Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) in the UK | GSK
LABA+LAMA, COPD 치료제 시장서 급부상 < 제약·바이오 < 기사본문 - e-의료정보
GSK 렐바 엘립타 시장 점유율 40% 돌파 < 제약산업 < 제약·유통 < 기사본문 - 의학신문
